Search International and National Patent Collections

1. (WO2018181759) COMBINED ANTICANCER AGENT SENSITIVITY DETERMINATION MARKER

Pub. No.:    WO/2018/181759    International Application No.:    PCT/JP2018/013340
Publication Date: Fri Oct 05 01:59:59 CEST 2018 International Filing Date: Fri Mar 30 01:59:59 CEST 2018
IPC: G01N 33/68
A61K 31/282
A61K 31/513
A61K 31/519
A61K 39/395
A61P 35/00
G01N 33/50
Applicants: KEIO UNIVERSITY
学校法人慶應義塾
KABUSHIKI KAISHA YAKULT HONSHA
株式会社ヤクルト本社
Inventors: SUGIMOTO, Shinji
杉本 伸二
TANIGAWARA, Yusuke
谷川原 祐介
MATSUO, Mitsuhisa
松尾 光寿
TAKAHASHI, Hiroyuki
高橋 寛行
Title: COMBINED ANTICANCER AGENT SENSITIVITY DETERMINATION MARKER
Abstract:
The present invention provides a new anticancer agent sensitivity determination marker. This sensitivity determination marker for anticancer agents contains oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, comprising at least one molecule selected from 2DG6P, 2MSE, CSSG, DOPM, GSSG, I4A, P2CB, 1-methyl-2-pyrrolidone, ASP, benzamide, glucaric acid, GL6P, Gly-Gly, HYPT and HYPX.